Skip to main content
CMAJ : Canadian Medical Association Journal logoLink to CMAJ : Canadian Medical Association Journal
. 2004 Sep 28;171(7):712. doi: 10.1503/cmaj.1041458

Correction

PMCID: PMC517844

The Health and Drug Alerts article on Zelnorm1 contained 2 errors. First, the complete description for Zelnorm is “the serotonin 5-HT4 receptor partial agonist, tegaserod (Zelnorm).” Second, the approximate number of people who will have very serious diarrhea is 1 in 2500 (or 0.04%), not 1 in 250 (or 0.4%) as stated in the article.

Reference

  • 1.Wooltorton E. Tegaserod (Zelnorm) for irritable bowel syndrome: reports of serious diarrhea and intestinal ischemia. CMAJ 2004;170(13):1908. [DOI] [PMC free article] [PubMed]

Articles from CMAJ : Canadian Medical Association Journal are provided here courtesy of Canadian Medical Association

RESOURCES